EVAH Closes Series B Financing of $8.5 million

EVAH Corp. (EVAH or the company) has announced the successful completion of a Series B financing round, raising $8.5 million. This additional financing brings EVAH’s total funding since its launch in 2020 to $28.5 million.

A business and development platform in the animal health industry, EVAH specializes in the development of vaccines to prevent bacterial diseases in food animals. The company also designs microbiome solutions for improved growth performance and medicated feed against parasites.

NewsGuest UserMarch 29, 2023BIOOQuébecEVAH, animal health, vaccine production

EVAH Announces Acquisition and Development Agreements for Four Technologies from Elanco

MONTRÉAL, QUÉBEC (May 25, 2021) – EVAH Corp. (EVAH or the Company) today announced the signing of four contracts with Elanco Animal Health Incorporated (NYSE: ELAN, Elanco) to acquire and develop technologies in animal health. EVAH is a biotechnology company specializing in the development of biologicals to help prevent bacterial diseases in food animals and microbiome solutions for growth performance.

NewsGuest UserMay 25, 2021EVAH, Elanco, animal health